Karen Jagoda’s Post

Cell and gene therapies (CGT), also known as “Advanced Therapy Medicinal Products” (ATMP), address diseases by directly repairing genetic defects within the body or introducing tissues or cells with new functions. These innovative therapies can correct or cure a wide range of conditions. The development and manufacture of these medicines are complex and novel, and they have only recently started gaining traction in the commercial sphere over the past decade. What sets them apart is their remarkable potential to offer permanent cures rather than temporary symptom reduction. Get an overview in the latest article by VTU experts Cornelia Haas and Birgit Krenn, which appeared in the magazine “botenstoff” of the Human.technology Styria GmbH (February 2024 issue, Precision Medicine special edition). #VTU #CellandGeneTherapy

 Are you testing therapeutics for ocular toxicity? See how retinal pigment epithelium models can be used to investigate efficacy of gene therapy vectors on both healthy and patient-derived tissues [ link to https://lnkd.in/eQxtFhrf] Speak to our experts to accelerate your research.

The “hf” in hfCas12Max stands for high-fidelity, and it’s not just a label—it's fact. hfCas12Max surpasses other common CRISPR nucleases by delivering high on-target editing with minimized off-target editing, which is critical for developing precise and effective #crispr -based cell and gene therapies. See for yourself how hfCas12Max is the right nuclease for you: https://lnkd.in/g7FjR7Gf

Souad Messahel, PhD, Elpida Therapeutics on Clinical Trials in Rare Diseases - Strategies for Resource Management, exploring the development costs for a biotech for a gene therapy. #ASGCT24, within the “Why Do Rare Disease Clinical Trials Often Miss The Mark” workshop

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

This Cystic Fibrosis Awareness Month, read MERIT's article to learn more about CFTR modulators and gene therapy treatments for rare mutations. https://lnkd.in/dvG994Eb #CysticFibrosis #respiratory #clinicaltrials #CysticFibrosisAwarenessMonth

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy

Osteoarthritis, one of the most common and debilitating chronic diseases, affects more than 30 million Americans, a number that is expected to increase exponentially as the population ages. Therapeutic options are limited. Current approaches start with nonpharmacological treatments such as walking aids, weight loss, and physical therapy, followed by acetaminophen and NSAIDS. Pioneers working on gene therapies for osteoarthritis and other chronic joint conditions won the prestigious OREF Award for 2024 at this year’s AAOS. One of the winners, Christopher Evans, PhD, discusses 30 years of research leading up to the founding of Genascence Corporation, which is now in clinical trials for a gene therapy for OA: https://bit.ly/3VDAh3R #medtech #osteoarthritis #chronicdisease #jointcondition #genetherapy